Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
| Autor: | Ingo G.H. Schmidt-Wolf, Nadine G D Schirmbeck, Ulrich Mey, Mathias Witzens-Harig, Dimitri Flieger, Yon-Dschun Ko, Ulrich Kaiser, Attilio Olivieri |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Salvage therapy Kaplan-Meier Estimate Dexamethasone 03 medical and health sciences 0302 clinical medicine Refractory Non-Hodgkin Lymphoma DHAP Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Aged Neoplasm Staging Salvage Therapy Chemotherapy business.industry Lymphoma Non-Hodgkin Cytarabine General Medicine Middle Aged medicine.disease Surgery Lymphoma Transplantation Regimen Treatment Outcome Drug Resistance Neoplasm 030220 oncology & carcinogenesis Retreatment Female Rituximab Cisplatin business 030215 immunology medicine.drug |
| Zdroj: | Cancer Investigation. 34:361-372 |
| ISSN: | 1532-4192 0735-7907 |
| Popis: | This analysis reports on 72 patients with relapsed or refractory non-Hodgkin lymphoma who were treated with R-DHAP salvage chemotherapy regimen followed by high-dose chemotherapy and stem cell transplantation. The overall remission rate was 58.3%. Median time of follow-up was 28.7 months. Median progression-free survival was 29 months, estimated median overall survival was 37 months. Within a matched pair analysis these results were compared to a group that received DHAP salvage therapy without rituximab showing similar overall response rates and better estimated five-year overall survival of 59.2% versus 43.5%. R-DHAP therapy was shown to be effective and feasible with acceptable toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |